TABLE 2.
Association of PVT1 gene expression and clinicopathological characteristics
| Characteristics | Levels | Low expression | High expression | p‐value |
|---|---|---|---|---|
| Demographic data | ||||
| Age, years | <55 year | 13 (81.3) | 32 (66.7) | 0.35 |
| ≥55 year | 3 (18.8) | 16 (33.3) | ||
| Sex | Male | 2 (12.5) | 12 (25) | 0.48 |
| Female | 14 (87.5) | 36 (75) | ||
| Pathological assessment | ||||
| Laterality | Unilateral | 12 (75) | 35 (72.9) | 0.87 |
| Bilateral | 4 (25) | 13 (27.1) | ||
| Histological variant | Classical | 8 (50) | 24 (50) | 0.77 |
| Follicular | 7 (43.8) | 17 (35.4) | ||
| Oncocytic | 0 (0) | 2 (4.2) | ||
| Tall cell | 1 (6.3) | 5 (10.4) | ||
| Pathology Stage | Stage I/II | 15 (93.8) | 38 (79.2) | 0.83 |
| Stage IVB | 1 (6.3) | 10 (20.8) | ||
| Tumor size | T1/2 | 9 (56.3) | 30 (62.5) | 0.48 |
| T3 | 7 (43.8) | 18 (37.5) | ||
| LN metastasis | Positive | 8 (50) | 27 (56.3) | 0.79 |
| Distant metastasis | Positive | 1 (6.3) | 10 (20.8) | 0.26 |
| Focality | Multifocal | 4 (25) | 20 (41.7) | 0.37 |
| ETE | Positive | 2 (12.5) | 9 (18.8) | 0.71 |
| LVI | Positive | 4 (25) | 5 (10.4) | 0.21 |
| Lymphocyte enrichment | Positive | 8 (50) | 23 (47.9) | 0.88 |
| BRAF V600E | Mutant | 7 (43.8) | 21 (43.8) | 0.99 |
| HCV antibody | Positive | 2 (12.5) | 19 (39.6) | 0.06 |
| Follow‐up | ||||
| Progression | Positive | 6 (37.5) | 23 (47.9) | 0.56 |
| Mortality | Died | 2 (12.5) | 9 (18.8) | 0.71 |
Data are represented as frequency (percentage).
Abbreviations: ETE: Extrathyroidal extension; LN: lymph node; LVI: Lymphovascular invasion. Progression: included recurrence, relapse, and distant metastasis. A two‐sided Chi‐square test was used. Statistical significance was set at p‐value <0.05.